Par
Used to treat chronic idiopathic constipation, as well as opioid-induced constipation in adult with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation. The drug is also used to treat irritable bowel syndrome with constipation in women at least 18 years old
1/4/2021
Daiichi Sankyo, Clover Biopharmaceuticals and Insilico Medicine made our news this week. (Google)
Amid a big cancer push, Daiichi Sankyo lured Kite Pharma exec Ken Takeshita to lead its R&D work. China s Clover Biopharmaceuticals secured $230 million in an oversubscribed series C to help advance its COVID-19 vaccine program and expand manufacturing capabilities. In several firsts for artificial-intelligence-based drug discovery, Insilico Medicine discovered a novel target for idiopathic pulmonary fibrosis, designed a new molecule and validated it in preclinical models in 18 months. And more.
Daiichi Sankyo, on its way to becoming a major cancer player, has poached Ken Takeshita, M.D., from Gilead Sciences’ cell therapy unit Kite Pharma to be its new global head of development and interim head of research, effective April 1. He takes over from Junichi Koga, Ph.D., who will retire after 12 years. The Japanese pharma has said it intends to develop seven new molecular entities fro
Dr Reddys announces launch of Lansoprazole DR Orally Disintegrating Tablets in US market
Hyderabad, Feb 21: Dr Reddy’s Laboratories Limited, along with its subsidiaries, together on Monday announced the launch of Lansoprazole DR Orally Disintegrating Tablets a therapeutic equivalent generic version of Prevacid SoluTab Delayed- Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Prevacid brand and generic had U.S. sales of approximately USD 87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health, a company release here said.
Dr Reddy’s Lansoprazole DR Orally Disintegrating Tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10).
The product is the generic of Takeda’s Prevacid SoluTab DR orally disintegrating tablets.
The Prevacid brand and generic had a market value of approximately $87 million, for the 12 months ended December 2020, according to IQVIA.
Dr. Reddy’s Lansoprazole DR orally disintegrating tablets are available in dosage strengths of 15-mg and 30-mg tablets in unit-dose packages of 100.
Dr Reddy s launches stomach, esophagus problems treatment drug in the US
SECTIONS
Last Updated: Feb 22, 2021, 12:37 PM IST
Share
Synopsis
Quoting IQVIA Health data, Dr Reddy s said the Prevacid brand and generic had US sales of approximately USD 87 million for the most recent 12 months ending in December 2020.
Agencies
Representative Image
Drug major Dr Reddy s Laboratories on Monday said it has launched Lansoprazole delayed release orally disintegrating tablets, used to treat certain stomach and esophagus problems, in the US market. The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA).